Review Article Fine-Needle Aspiration Cytology Can Play a Role in Neoadjuvant Chemotherapy in Operable Breast Cancer

License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Despite the fact that CNBhas been progressively replaced by FNAC in the investigation of nonpalpable lesions ormicrocalcifications without a clinical or radiological mass lesion, FNAC has yet a role in palpable lesions provided it is associated with the triple diagnosis and experienced cytologist. In these conditions, FNAC is a safe, effective, economical, and accurate technique for breast cancer evaluation. Numerous literature reviews and meta-analyses illustrated the advantages and disadvantages of both methods CNB and FNAC.The difference does not seem significant when noninformative and unsatisfactory FNAC was excluded. Recently, cytological methods using liquid-based cytology (LBC) technology improve immunocytological andmolecular tests with the same efficiency as classical immunohistochemistry.The indications of FNACwere, for palpable lesions, relative contraindication of CNB (elderly or frailty), staging of multiple nodules in conjunction or not with CNB, staging of lymph node status, newly appearing lesion in patient under neoadjuvant treatment, decreasing of anxiety with a rapid diagnosis, evaluation of biomarkers and new biomarkers, and chronological evaluation of biomarker following the neoadjuvant therapy response. 1